• Hesperadin: Aurora B Kinase Inhibitor Guide

  2026-08-19

  Hesperadin is an ATP-competitive Aurora B kinase inhibitor that disrupts histone H3 Ser-10 phosphorylation and mitotic chromosome behavior. Its biochemical potency, HeLa-cell phenotype, solvent profile, and checkpoint relevance make it a useful research tool rather than a clinical treatment claim.

• CH 223191 Workflows for AhR Mechanistic Studies

  2026-08-19

  CH 223191 enables controlled interrogation of AhR activity across dioxin toxicology, epithelial differentiation, and microbiota-linked intestinal repair models. This practical workflow connects concentration planning, CYP1A1 readouts, organoid assays, and troubleshooting for reproducible environmental toxicology research.

• Adefovir: From HBV Assays to Renal Risk

  2026-08-18

  Adefovir and GS-0393 offer a powerful model for studying HBV DNA polymerase inhibition and OAT1-mediated renal handling. This article connects antiviral assay design with a clinically important, evidence-based framework for detecting phosphate-wasting toxicity and interpreting translational exposure.

• Canagliflozin: SGLT2 Inhibitor Research Guide

  2026-08-18

  Canagliflozin is a selective SGLT2 inhibitor that suppresses renal glucose reabsorption and increases urinary glucose excretion. Recent mouse data link treatment with proximal tubular mitochondrial remodeling, improved bioenergetics in males, and reduced albuminuria.

• A20, Oxidized DNA, and Acute Kidney Injury

  2026-08-17

  The reference study identifies oxidized self-DNA as an inflammatory driver in acute kidney injury and shows that A20 limits this response by restraining STING signaling and NLRP3-mediated pyroptosis. Its mechanistic and peptide-validation data position the A20–NEK7 interaction as a potential therapeutic entry point, while also providing a framework for interpreting inflammasome modulation in related disease models.

• Berberine Hydrochloride: AMPK Research Workflows

  2026-08-17

  Berberine hydrochloride is a defined chemical probe for connecting AMPK-driven metabolic regulation with LDL receptor, mitochondrial, oxidative-stress, and cancer readouts. This workflow shows how to move from reproducible DMSO stocks to cell-based assays, cardiotoxicity models, and troubleshooting decisions without overextending evidence from botanical extracts.

• Sitagliptin Phosphate Monohydrate in Gut Signaling

  2026-08-16

  Sitagliptin phosphate monohydrate is a selective DPP-4 inhibitor that can help separate incretin-dependent glucose regulation from intestinal stretch signaling. This article translates recent gut mechanosensation findings into practical assay and study-design decisions.

• Hypoxia and Immunometabolism in the Tumor Microenvironment

  2026-08-15

  This 2025 review frames tumor hypoxia and immunometabolism as a reciprocal system in which oxygen limitation, nutrient competition, and HIF signaling reshape both malignant and immune-cell behavior. Its main practical implication is that tumor progression and therapeutic response should be interpreted through coordinated metabolic, immune, and redox measurements rather than through isolated molecular endpoints.

• 3-Deazaneplanocin (DZNep) in Cancer Research

  2026-08-14

  3-Deazaneplanocin (DZNep) connects S-adenosylhomocysteine hydrolase inhibition with functional EZH2 suppression, making it useful for apoptosis induction in AML cells, hepatocellular carcinoma research, and cancer stem cell targeting. This workflow-driven guide covers dose design, epigenetic readouts, model stratification, and troubleshooting for reproducible experiments.

• Vaccinia F1L Evasion of NLRP1 Activation

  2026-08-14

  The reference study identifies vaccinia virus F1L as a viral antagonist that suppresses dsRNA- and ribotoxic stress-driven NLRP1 inflammasome activation while leaving DPP9-inhibition-mediated activation intact. Its genetic, cellular, and translation-focused experiments place F1L function partly upstream of ZAKα, clarifying how vaccinia virus limits epithelial innate immune signaling.

• Rucaparib and the Logic of DNA Repair Dependency

  2026-08-13

  Rucaparib (AG-014699) is examined here as a causal tool for DNA damage response research, not simply as a PARP inhibitor. The article connects repair-pathway phenotypes with a key Pol II degradation study and translates that distinction into more rigorous assay design.

• Talabostat mesylate: CARD8 and FAP Assays

  2026-08-13

  Talabostat mesylate, also called PT-100 or Val-boroPro, supports complementary workflows for DPP4/FAP biology, tumor-stroma studies, and CARD8-dependent pyroptosis. This guide connects FAP-expressing models with resting human T-cell assays while emphasizing controls that prevent mistaking broad DPP engagement or solvent effects for pathway-specific biology.

• PMSF in Cardiomyocyte Ablation Research

  2026-08-12

  Explore how Phenylmethanesulfonyl fluoride (PMSF) can strengthen protein-level measurements after microsecond pulsed electric field ablation. This article distinguishes proteolysis control from apoptosis mechanism and translates recent cardiomyocyte findings into practical assay decisions.

• Moesin in Sepsis: Endothelial Injury Biomarker

  2026-08-12

  The reference study identifies circulating moesin (MSN) as a candidate biomarker of endothelial injury and sepsis severity, linking serum levels with SOFA scores, procalcitonin, and experimental lung damage. Its combination of patient samples, mouse sepsis models, and mechanistic endothelial-cell experiments suggests that MSN is not only associated with vascular dysfunction but may also participate in Rock1/MLC and NF-κB signaling.

• Canagliflozin Workflows for Renal Mitochondria

  2026-08-11

  Canagliflozin enables researchers to connect renal glucose handling with proximal tubular mitochondrial structure and bioenergetics. This practical guide outlines formulation, cell-based, animal-model, imaging, and respiration workflows while emphasizing sex-aware analysis and troubleshooting.

8033 records 2/536 page Previous Next 12345 下5页 Last page